Preliminary guidelines for the off-label use of calcium hydroxylapatite (CaHA) for biostimulation in the face and body has been published in Dermatologic Surgery.
A global panel of 14 aesthetic practitioners specialising in dermatology, plastic surgery, and oculoplastic surgery, including UK practitioner Dr Kate Goldie, convened to develop consensus-based guidelines for treating laxity and superficial wrinkles using diluted (ratio of 1:1) and hyperdiluted (≥1:2) CaHA.
The practitioners documented their clinical experience with Radiesse and provided guidelines for its use to stimulate targeted neocollagenesis and act as a biostimulatory agent.
They describe its use in the face, neck and décolletage, upper arms, lower body, including the abdomen and buttocks, as well as cellulite, stretch marks and the legs.
The authors stated, “CaHA appears to promote dermal remodeling through stimulation of collagen and elastin for a skin-tightening effect and to improve superficial wrinkles, elasticity, and skin thickness. Because the evidence in the literature to support this practice is limited at present, this report provides preliminary guidelines for the novel, off-label use of CaHA as a biostimulatory agent in the face and body with the expectation that future rigorous clinical trials will provide further evidence for optimal outcomes.”
Radiesse is developed by Merz Pharmaceuticals and is currently FDA approved to correct moderate-to-severe wrinkles and folds and soft-tissue volume loss in the face and hands.